Pregabalin + Pregabalin

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Epilepsy, Complex Partial

Conditions

Epilepsy, Complex Partial

Trial Timeline

Apr 1, 2010 → Jul 1, 2014

About Pregabalin + Pregabalin

Pregabalin + Pregabalin is a approved stage product being developed by Pfizer for Epilepsy, Complex Partial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01128712. Target conditions include Epilepsy, Complex Partial.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy, Complex Partial were approved

Approved (20) Terminated (6) Active (0)

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01128712ApprovedTerminated

Competing Products

20 competing products in Epilepsy, Complex Partial

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35